In ten minutes a day, You too can be ON TOP of the biopharma industry
Call John D Waddell, RPh @ +1-610-952-1871
TSM Associates are…
Creative
Experienced
Committed
BioPharma Industry News
-
Novo Nordisk pays $700M for anti-infective developer, Xellia
-
Regeneron, Sanofi's dupilumab may be asthma game changer
-
SCOTUS: Plaintiffs in 'vax court' can ask govt to cover legal fees
-
Shire may pay $3B dividend or seek M&A to avoid takeover
-
Which biotech conferences should you attend?
-
Biogen files FDA BLA for subQ peg-IFN beta-1a, Plegridy in MS
-
Drug cargo thefts are up again this year; $173K per heist
-
GSK creates competition for academic researchers
-
Investors skeptical of Teva plans to reformulate old drugs
-
KPMG report: China's pharma industry should consolidate
-
NanoString Technologies preps for $86M IPO
-
PatientsLikeMe opens health outcomes hub for research
-
PCMA: Overwhelming satisfaction w/ closed pharmacy networks
-
Pfizer ends inotuzumab lymphoma Ph 3; Won't help survival
-
Pharmas dial back reprints, spend it on digital for HCPs
-
Bayer: Extended use of riociguat safe and effective in PAH
-
Critics of IP system: Simply not suitable for developing world
-
Cubist wins in federal Cubicin patent case versus Hospira
-
Dirty medicine: Inside the long-term criminal fraud @ Ranbaxy
-
Dismissal of GPO chief would disrupt Thailand's dist Sx
-
FDA Staff: Merck's suvorexant effective in sleep w/ dose-dep AE's
-
FDA stunts growth of molecular med w/ adaptive trial stance
-
Karyopharm gets $48.2M in Ser B for nuclear transport drugs
-
Lundbeck & Takeda's vortioxetine wins 2 Ph 3 depression trials
-
Takeda's GPR40 agonist, fasiglifam shines in Ph 3 for diabetes
-
UK first in EU to get Merck's new Schmallenberg vax
-
UNC: Pricey radiation no better post prostatectomy
-
Actavis pays $5B in stock for Warner Chilcott & Irish tax rate
-
Aegerion leads biotech winners; Infinity leads weekly losers
-
AHRQ report: Interventions for provider adherence in asthma
-
AstraZeneca: Dividend payer with attractive growth prospects
-
B6 & B12 with folic acid slow atrophy of brain in Alzheimer's
-
Biotech surge creates a record breaking start to 2013
-
Chimeric antigen receptor may be like "penicillin for leukemia"
-
Cystic Fibrosis Foundation dives into venture capitalism
-
Dr Reddy's welcomes India's new drug pricing policy
-
Feds charge 3 NYU researchers for accepting Chinese bribes
-
Is our health care spending slowdown for real?
-
Many Europeans cannot afford meds in global economic crisis
-
Pentagon advisor touted anti-anthrax drug while on mfr's board
-
Rising funding competition leads to ethical lapses, retractions
-
Royalty Pharma raises bid for Elan & Tysabri royalties to $4.6B
-
UK program to allow more people to undergo Ca gene testing
-
'Lipstick effect' hits China: Fewer spend on small indulgences
-
Chinese pharmas get access to Western mrkts via JV's
-
Elan buys Orphan & NewBridge in deals worth $380M
-
FDA guidelines on expanded access to experimental drugs
-
FDA schedules HIV patient-focused drug devt meeting
-
Intercept: OCA looks good in Ph 2a for chronic bile diarrhea
-
Ketamine relieves hard-to-treat depression in largest study yet
-
Peregrine & FDA agree on bavituximab Ph 3 design in lung Ca
-
Pfizer's failed Exubera tech, oxytocin cut maternal mortality
-
Reform bill takes aim at 'gray market' role in drug shortages
-
Sangamo & Shire's in vivo factor VIII tech looks good in mice
-
Synageva's sebelipase alpha, a "breakthrough" in Wolman dis
-
US Supreme Court to hear Medtronic v. Boston Sci patent case
-
XenoPort to drop arbaclofen in MS after Ph 3 trial failure
-
AstraZeneca closes in on site for new HQ in Cambridge, UK
-
Brother & sister in WI 2 of 1200 in US aided by Vertex' Kalydeco
-
Greying China taps rural elderly to care for those even older
-
Harvard Biz Rev: Generic corp culture steeped in greed & dysf(x)
-
India caps prices on 650 drugs; GSK, Sanofi hit hardest
-
It's been another IPO-intensive couple of weeks in biopharma
-
Point-counterpoint on mounting concerns with GLP-1 drugs
-
Puma up as GSK's Tykerb shows no threat to neratinib in MBC
-
Sanofi reports Ph 3 myelofibrosis win for JAK2 inh, SAR302503
-
ZS: "Geeks.. running the numbers..helping..sales..be efficient"
-
Bayer has received 3 FDA oncology approvals in last 8 mos
-
DSM 5: Too many major changes with limited evidence?
-
DSM-IV task force chair presses attack on DSM-V
-
GSK bets on volume growth with emerging markets price cuts
-
Oramed gets FDA IND clearance to start US oral insulin trials
-
Roche & QB3 team up to launch startups in the Bay Area
-
Valeant wants Activis which wants Warner Chilcott.. & on & on
-
XBiotech takes aim at inflammation that weakens Ca patients
-
AbbVie gives Galapagos $50M for more for JAK1, GLPG0634
-
Calm on Cleveland Clinic Ca ward. Beautiful sun rises over water
-
CMS has $1B in grants to "rapidly reduce" Medicare spending
-
FDA AE d'base ID's issues w/ 5-HT3's, metoprolol succinate ER's
-
FDA guidance & Sunshine regs: Divergent paths, redundancies
-
Fever-reducing drugs don't speed recovery from infection
-
Global biosimilars mrkt forecasted to $2.445B in 2013
-
MA rep reintroduces legislation for clinical trial data transparency
-
Novartis scientists make synthetic H7N7 flu vax in one week
-
Novo completes first Ph 3 for N9-GP in hemophilia B
-
Purdue & Transcept pull Intermezzo DTC & cut 90 contract reps
-
Risperdal suits keep on coming; Kentucky sues J&J
-
Scotland ignores conventional wisdom with bold steps vs hep C
-
Warner Chilcott buy may be Actavis' best takeover defense
-
We're beginning to understand how bugs keep us healthy
-
WHO reports 1st patient-to-nurse spread of SARS-like virus
-
AHRQ: Urgent improvement needed in quality of diabetes care
-
Australian judge invalidates Merck Vioxx class action settlement
-
EMA releases ICH guideline on mfrg impurities for consultation
-
Evotec & Harvard partner to develop new antibacterials
-
Impax begins shipping auth generic of AstraZeneca's Zomig
-
Medicare spending projections are plummeting - The Atlantic
-
Novartis' Vasella exit opens door to Roche stake sale
-
OnDeck Biotech: Online connection for biotechs & contract services
-
Pharma seeks flexibility in rating Antibiotics Incentives Now Act
-
Psychs unveil long-awaited diagnostic "bible", DSM-V
-
Rib-X & Ligand start Ph 3 for delafloxacin in ABSSSI
-
Roche & Biogen file for re-hearing of GSK Arzerra appeal
-
Sanofi & French govt at odds on plans for Toulouse R&D site
-
Teva treads lightly in morning-after controversy
-
Wireless pill bottle wins Healthcare Innovation World Cup
-
EMA: Bayer's Diane 35 & generics safe for appropriate acne use
-
FDA guidance on e-health data, pooled data in Ph 4 studies
-
J&J faces criminal charges in South Korea over Tylenol mfrg
-
NEJM: Is FDA approving too many drugs starting with 'X' & 'Z'?
-
Novartis says it has no intention of buying Actavis
-
Off-label drug use to boost cognitive performance in UK
-
On a price-quality ratio, Switzerland has best healthcare
-
UCB & IBM system to translate big data @ point of epilepsy care
-
US children's mental illness costs $247B per year and is rising
-
107 drug recalls documented in 1Q13, up from 4Q12 & 1Q12
-
2 regions in South & mid-Atlantic have 4x avg sepsis death rate
-
Alliance Boots plans to double China ops within two years
-
AMA's 2012 profit down by a third despite 3.2% membership rise
-
Ambit forced to offer a deep discount on IPO shares
-
Amgen, Novartis join Atlas Venture in $265M biotech fund
-
Anaphore changes name to RuiYi & focus to biologics for China
-
ASCO: PD-1 & PDL-1, cell death drugs, may be the biggest news
-
AstraZeneca: Moxetumomab, olaparib & selumetinib go to Ph 3
-
Bayer buys private Steigerwald Arzneimittelwerk herbal meds
-
Big pharma fears India's patent battle will inspire others
-
BMS data suggests cocktail approach to advanced melanoma
-
Brainwashed: The seductive appeal of mindless neuroscience
-
Chemo, radiation & radioactive follow-up not always needed
-
Cubist bid $1B for Optimer before sale process even began
-
Docs & ethicists dispute patient need for genome/exome info
-
Evidence "implementation gap" at small-to-mid-size biotechs
-
Ex-NICE chair's appt to Intra-Cellular board raises COI fears
-
FDA approves J&J's anti-TNF, Simponi for ulcerative colitis
-
FDA loosens regs on 'smart pills' transmittig messages from GI
-
FDA warning didn't change for-profit dialysis drug use
-
Fitch puts RPI on negative watch over intent to acquire Elan
-
Genfit's dual PPAR, GFT505 cuts remnant cholesterol CV risk
-
Myriad BRCA 1&2 case is tip of 'genomic freedom' iceberg
-
NEJM: Intense surveillance of H7N9 virus is warranted
-
New tools help patients decide when to skip chemotherapy
-
NIH looks to reformulation, social media vs opioid abuse
-
Novo CEO scolds EU officials for 'empty promises' on new drugs
-
Office for Human Research Protections wrong on risk & consent
-
Pharmas are cool with YouTube but fear Twitter
-
Pundits use of single ACA studies/data inapt vs fundamentals
-
Quest Diagnostics acquires Humana's Concentra lab biz
-
Ranbaxy perpetuated systemic cover-up for nearly a decade
-
Roche exploring sale of diabetes device biz: Medtronic, J&J?
-
Roche's MPDL3280A well tolerated & effective in variety of Ca's
-
Sanofi taps Jerome Bettis for anaphylaxis campaign, Auvi-Q
-
Stemline prices $60M public offering of common stock
-
Sweden's Recipharm looks to sell or list in Stockholm
-
Synthetic biology may hasten the development of flu vaxes
-
Tekmira's RNAi for Ebola achieves critical milestone
-
ThromboGenics: US sales of Jetrea top $10M in 2013
-
UK Office of Fair Trading accuses GSK of pay-for-delay
-
WHO: "Dramatic" life expectancy gains show no sign of slowing
-
WHO's cash prizes vs patents good enough to scare pharma
-
"Very strong relationship" w/ fitness & middle-age Ca survival
-
"Weight loss gut bacterium" found... ...for mice
-
100 best-selling pharmaceuticals in 1Q13 (retail & hospital)
-
43 AGs ask FDA urged to place Black Box Warning on opioids
-
AbbVie gives Alvine $70M upfront for AVL003, anti-gluten drug
-
Actavis rejected Mylan's $15B bid to pursue Warner Chilcott
-
Alliance Boots defends tax pmts; Corp tax modest part of total
-
Animal-rights & and disease activists target Merck leaders
-
Are trials to compare efficacy of biosimilars even ethical?
-
Bayer starts liver Ca Ph 3 for potential blockbuster, regorafenib
-
BMS targets heart-failure and fibrosis drugs in R&D effort
-
Brazil generics mrkt expected to grow dramatically by 2020
-
Community screenings at hospitals make overtreatment worse
-
Did Elan overpay on Theravance to spurn hostile suitor?
-
Drug biz pushes back against refill reminder rule; 100M per yr
-
FDA approves Arbor's Nymalize in brain hemorrhage
-
FDA approves Bayer's Xofigo in adv prostate Ca w/ bone mets
-
FDA approves EGFR companion diagnostic for Roche's Tarceva
-
FujiFilm pays $10/60M for Cempra's solithromycin in Japan
-
Gilead's oral idelalisib effective in Ph 1 in recurrent CLL
-
Hambug on mfrg standards: How good is good enough?
-
HHS' $1B initiative to fund innovations in federal health programs
-
In mass customization era, big data approach is a little odd
-
India unveils cheap alternative to GSK, Merck rotavirus vaxes
-
Kite Pharma gets $35M in Ser A for Ca immunotherapies
-
Like it or not, researchers & scientists, you're in sales
-
Lipitor generics help NHS save $1.52M per day
-
Medicare Drug Savings Act 2013: Hospitals profit from 340B
-
Omeros closes $16.2M direct offering with 2% premium
-
OR lesson: Want to improve health care? Spend less on it
-
Pfizer recs normal dividend & special animal health dividend
-
Poliwogg & Microryza: New crowdfunding initiatives for biotech
-
ProPublica: Part D fails to monitor prescribers, puts pats @ risk
-
Quintiles & Merck KGaA sign 5-year exclusive R&D deal
-
Ranbaxy may resume exports after resolving criminal charges
-
Roche says CLL data for GA101 will top MabThera pre-expiry
-
Samyang licenses Cynviloq, paclitaxel to Sorrento & Igdrasol
-
Sanofi & Regeneron start recruiting Ph 3 RA trials for sarilumab
-
Sanofi taps PatientsLikeMe.com to recruit for clinical trials
-
Sequencing cost deceleration may be slowing
-
Surge in dengue fever cases prompts UK to warn travelers
-
The Street reiterates GSK as a buy on revenue growth
-
The weird and wonderful world of 3D printing
-
Tokai gets $35.5M in Ser E for galeterone in prostate Ca
-
Treatment guidelines for pediatric ADHD rarely followed
-
Univ of OR scientists create human stem cells through cloning
-
US DOJ charges 89 defendants in 8 cities with health fraud
-
US Senate confirms Tavenner as Medicare/Medicaid chief
-
WHO data shows narrowing health, child mortality gap
-
WHO: Viet Nam vax deaths with J&J Quinvaxem coincidental
-
Astellas shuts down OSI, Perseid in restructuring of R&D
-
AstraZeneca, Astellas & Cubist M&A reports lift Optimer shrs
-
Biotech shrs off to best start since inception w/out approvals
-
CA SB 598 would allow substitution of lower-cost biosimilars
-
Cornell cocaine vax shows promise in monkey trial
-
FDA accepts Biogen BLA for long-lasting Eloctate in hemoph A
-
FDA approves lower doses for zolpidem sleep drugs
-
FDA moves give Purdue an edge in opioid analgesic market
-
FDA slams Endo for misuse of data in Opana ER Citizen Petition
-
FDA strategies to Prevent and respond to drug shortages
-
FDA to study of use of composite scores in DTC advertising
-
French regulator fines Sanofi $53M for generic 'smear campaign'
-
House panel is investigating resignation of top FDA official
-
Huge drug cost disparities undermine Obamacare (esp Ca)
-
Immune-boosting Ca drugs may signal paradigm shift
-
Industry confronts healthcare's changing oncology practices
-
Isis: Has RNA therapeutics & orphan drug devt frenzy died?
-
J&J unit gets priority revenue for simeprevir NDA in hep C
-
JAMA: Adult-observed ADHD reflects, validates true rate in kids
-
Lancet: Inoculating communities against vaccine scare stories
-
Merck KGaA expects to achieve 2014 guidance a year early
-
Middle East coronavirus & H7N9 could both spark global outbreaks
-
NEJM: MA PCOC sites old data to support anti industry bias
-
Novartis kickback cases, a shift toward civil vs criminal charges
-
P&T: Proposed FDA approval criteria for biosimilars
-
Pharma and CRO execs question sponsor oversight of CROs
-
Radius to post Ph 2 data for osteoporosis patch, BAO58 in Sep
-
Ranbaxy pays DOJ $500M to settle long-running mfrg scandal
-
SEC investigating Spectrum on steep drop in Fusilev sales
-
Shire's Nimbus Rare dis deal: Interesting science & financing
-
Stem cell industry approaching highly visible Ph 2 & 3 catalysts
-
Teva considering the acquisition of Adcock Ingram
-
Vivus adds two new directors to board amid pressure
-
Walgreen, CVS extend Mmulti-year pharmacy network deal
-
"Encouraging" signs for e-Therapeutics' ETS2101 in Ph 1 for oesophageal Ca
-
10 ASCO 2013 abstracts you can read right now
-
10% of congenital heart defects from spontaneous mutations
-
Agent Orange tied to aggressive prostate Ca risk
-
Alethia gets US patent for mBs targeting secreted clusters in epithelial-to-mesenchymal metastasis
-
AmerisourceBergen completes divestiture of Andersonbrecon pkg biz
-
Assoc of Clinical Research Orgs creates new video series for YouTube
-
Astellas, Daiichi Sankyo say new drugs will Propel growth
-
AstraZeneca: Assessing your asthma is key to taking control
-
Big pharma is selling far fewer pills, but at a much higher price
-
Biohit Oyj sees promise in China for Acetium GI Ca prevention
-
Biopharma winners led by Warner Chilcott; Losers, Optimer
-
Bluebird bio & PTC Therapeutics mount campaigns to go public
-
Callidus raises $4.6M in a private stock sale for ultra rare dis(s)
-
Canada recalls quetiapine generics on antibiotic contamination
-
Cautious optimism healthcare spending growth has slowed
-
CDER solicits comments on product devt R&D and promo issues
-
Charity & big pharma are uneasy bedfellows: Is it way forward?
-
Chiasma fires a third of workforce despite Roche Octreolin deal
-
Drug companies blast WA county's pill disposal plan
-
Dyax prices $30M diect offering to develop DX-2930 in HAE
-
Edarbyclor is only ARB chlorthalidone combination on the mrkt
-
Elan sheds further light on plans to rebuild its business
-
Elan to pay $1B for stake in Theravance respiratory royalties
-
FDA accepts Seagen's sBLA for Adcetris retreatment and extended duration
-
FDA OK's Intercell's Ixiaro Japanese Encephalitis vax for ped use
-
FDA patient Web site seeks engagement in decision-making
-
Fears grow as WHO says coronavirus is communicable
-
Former breast Ca Action exec dir dies at 61 of ALS
-
Former Merck pipefitter files suit over job assignment
-
Fresenius SE eyes small and mid-sized acquisition targets
-
Goldman Sachs invests $20M in Indian medical device maker
-
Grifols licenses Aradigm's Pulmaquin, ciprofloxacin in non-cystic fibrosis
-
Halozyme rises on Ph 1 data for PEGPH20 in pancreatic Ca
-
Health reform underscores need to engage patients before trials
-
High valuations transform biotechs from targets into buyers
-
Israel tells Teva to pay more taxes after 0.3% rate paid in 2011
-
J&J outlines poppy supply plans beyond Tasmania
-
Jury out in another jawbone death case for Novartis' Zometa
-
Karyopharm raises $20.5M for Ca drugs, KPT-330 & KPT-335
-
Medicines patent pool: Big pharma's toe still in the water
-
Michael J Fox back in prime-time; Parkinson's in check w/ meds
-
Moody's lowers Merck's long-term debt rating
-
Mylan gets FDA approval for generic of AbbVie's Tricor
-
NEJM: Only 5-6% of US hep C pats have been successfully treated
-
Novartis considers bid for Actavis as battle heats up
-
Novartis properly warned of Zometa's risks, jury decides
-
NYC wins $70M from 44 biopharmas in Medicaid fraud suit
-
Obesity obsession misses problem of underweight children
-
Oncothyreon's failed lung Ca vax, Stimuvax might be more effective following concurrent chemo-radiation
-
Pakistani minister does not expect drug prices to rise
-
Patent expires in 2012 contributed $28.9B decline in drug spend
-
Pfizer lays off 25 in Bristol, TN after 2nd Levoxyl recall
-
Pfizer to close mfrg plant in Ireland
-
Plan to provide NJ Sanofi facility with solar power postponed
-
Practicing psychiatrists will pay little attention to DSM-5
-
Psych's big new battleground; Does mental illness really exist?
